BioCentury | Jul 21, 2014
Company News

NanoCarrier, Eisai deal

...Eisai granted NanoCarrier an exclusive, worldwide license to develop and commercialize Eisai’s E7974 for cancer. NanoCarrier...
...showed that applying ADCM to E7974 expands the compound’s therapeutic window by about 10 times. E7974...
...said Eisai would “most likely” be able to exercise its right of first refusal after E7974...
BioCentury | Mar 26, 2007
Strategy

Building a cancer pipeline

...lung Ph I E7820 Anti-angiogenesis agent Various Ph I E7080 Anti-angiogenesis agent Various Ph I E7974...
Items per page:
1 - 2 of 2